1 period filed. Holdings below describe the selected month only.
NPORT-P · filed 2026-06-29
9 classes of this one portfolio · 0 exchange-listed
| Class ID | Symbol | Status | Security in the master | Type |
|---|---|---|---|---|
| C000208658 | LHCAX | NOT_LISTED | not exchange-listed | — |
| C000208659 | LHCCX | NOT_LISTED | not exchange-listed | — |
| C000208660 | LHCFX | NOT_LISTED | not exchange-listed | — |
| C000208662 | LHCIX | NOT_LISTED | not exchange-listed | — |
| C000208661 | LHCOX | NOT_LISTED | not exchange-listed | — |
| C000208664 | LHCQX | NOT_LISTED | not exchange-listed | — |
| C000208665 | LHCSX | NOT_LISTED | not exchange-listed | — |
| C000208667 | LHCTX | NOT_LISTED | not exchange-listed | — |
| C000208666 | LHCVX | NOT_LISTED | not exchange-listed | — |
N-PORT Item C.4.a
as filed
N-PORT Item C.4.b
64 positions in this filing
| Issuer↕ | In master | CUSIP / ISIN | Asset | Balance↕ | Value↕ | Weight▼ | Country |
|---|---|---|---|---|---|---|---|
| Newamsterdam Pharma Co NV | NAMS | 000000000 NL00150012L7 | EC CORP | 1,944 NS |
| 0.682% |
| NL |
| Alumis Inc | ALMS | 022307102 US0223071020 | EC CORP | 2,183 NS | $53.9K | 0.662% | US |
| Nuvalent Inc | — | 670703107 US6707031075 | EC CORP | 520 NS | $52.1K | 0.640% | US |
| Samsung Biologics Co Ltd | — | 000000000 KR7207940008 | EC CORP | 51 NS | $50.8K KRW | 0.624% | KR |
| Repligen Corp | RGEN | 759916109 US7599161095 | EC CORP | 425 NS | $50.3K | 0.617% | US |
| IDEXX Laboratories Inc | IDXX | 45168D104 US45168D1046 | EC CORP | 89 NS | $49.9K | 0.613% | US |
| Roivant Sciences Ltd | ROIV | 000000000 BMG762791017 | EC CORP | 1,451 NS | $41.4K | 0.508% | BM |
| Oruka Therapeutics Inc | ORKA | 687604108 US6876041087 | EC CORP | 603 NS | $41.3K | 0.506% | US |
| Apogee Therapeutics Inc | APGE | 03770N101 US03770N1019 | EC CORP | 487 NS | $40.4K | 0.496% | US |
| Scholar Rock Holding Corp | SRRK | 80706P103 US80706P1030 | EC CORP | 822 NS | $38.3K | 0.470% | US |
| RadNet Inc | RDNT | 750491102 US7504911022 | EC CORP | 672 NS | $38.0K | 0.467% | US |
| ORIC Pharmaceuticals Inc | ORIC | 68622P109 US68622P1093 | EC CORP | 3,130 NS | $30.9K | 0.380% | US |
| Citibank NA CITIBANK NA DDCA | — | 000000000 — | STIV RF | 15,547.5 NS | $15.5K | 0.191% | US |
| Argenx SE | — | 000000000 NL0010832176 | EC CORP | 7 NS | $5.5K EUR | 0.067% | NL |
Positions resolved to the master through ISIN, then rolled up through the taxonomy. 84.5% of reported value reaches a classification.
Percentages are of the reported value of positions above ($8.30M), not of the fund’s net assets ($8.15M). The two differ by cash, derivatives filed with no market value, and rounding.